Literature DB >> 18205790

Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-stimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via down-regulation of mitogen-activated protein kinase-mediated nuclear factor-kappaB signaling.

Niranjan Rajapakse1, Moon-Moo Kim, Eresha Mendis, Se-Kwon Kim.   

Abstract

Glucosamine (GlcN) has been reported to possess several biomedical properties, and currently a great deal of attention has been focused on improving the functional properties of GlcN for different applications. Therefore, this study was conducted to introduce a carboxybutyryl functional group to GlcN and to find out the inhibitory mechanism of a novel GlcN derivative, carboxybutyrylated GlcN (CGlcN), on the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in bacterial lipopolysaccharide (LPS)-induced mouse macrophages (RAW264.7 cells). In the initial experiments, the production of NO and prostaglandin E(2) (PGE(2)) was inhibited by CGlcN pretreatment and suggested the possibility of down-regulating their respective genes, iNOS and COX-2. Reverse transcription-polymerase chain reaction and Western blot analysis revealed that CGlcN can affect both transcriptional and translational levels of iNOS and COX-2 expression. The data from the nuclear factor-kappaB (NF-kappaB) promoter gene transfection experiment supported the idea that inhibition of iNOS and COX-2 is caused by the down-regulation of their transcription factor, NF-kappaB. Following stimulation with LPS, p38 mitogen-activated protein kinase (p38 MAPK) and c-Jun N-terminal kinase (JNK) present upstream of NF-kappaB signaling were also inhibited by CGlcN treatment. However, the protein level of another MAPK, extracellular signal-regulated kinase (ERK), remained unaffected. Moreover, following treatment with CGlcN, the protein expression of I-kappaB kinase (IKK) clearly confirmed that its down-regulation directly inhibited the degradation of IkappaB and release of NF-kappaB. Therefore, it can be concluded that CGlcN is capable of inhibiting iNOS and COX-2 expression in LPS-induced RAW264.7 cells via attenuation of NF-kappaB signaling by p38 MAPK and JNK, but not by ERK.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18205790      PMCID: PMC2433337          DOI: 10.1111/j.1365-2567.2007.02683.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

1.  Oxygen metabolism by neuronal nitric-oxide synthase.

Authors:  Ying Tong Gao; Satya Prakash Panda; Linda J Roman; Pavel Martásek; Yuzuru Ishimura; Bettie Sue S Masters
Journal:  J Biol Chem       Date:  2007-01-17       Impact factor: 5.157

Review 2.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

3.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

Authors:  M B Hansen; S E Nielsen; K Berg
Journal:  J Immunol Methods       Date:  1989-05-12       Impact factor: 2.303

4.  Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids.

Authors:  L C Green; D A Wagner; J Glogowski; P L Skipper; J S Wishnok; S R Tannenbaum
Journal:  Anal Biochem       Date:  1982-10       Impact factor: 3.365

Review 5.  Natural products as targeted modulators of the nuclear factor-kappaB pathway.

Authors:  Paul Bremner; Michael Heinrich
Journal:  J Pharm Pharmacol       Date:  2002-04       Impact factor: 3.765

6.  Potential role of NO in modulation of COX-2 expression and PGE2 production in pancreatic beta-cells.

Authors:  Jia-Jian Ling; Yu-Jie Sun; Dong-Ya Zhu; Qi Chen; Xiao Han
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2005-02       Impact factor: 3.848

7.  Glucosamine inhibits inducible nitric oxide synthesis.

Authors:  C J Meininger; K A Kelly; H Li; T E Haynes; G Wu
Journal:  Biochem Biophys Res Commun       Date:  2000-12-09       Impact factor: 3.575

8.  Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase.

Authors:  Q W Xie; Y Kashiwabara; C Nathan
Journal:  J Biol Chem       Date:  1994-02-18       Impact factor: 5.157

9.  Eugenol suppresses cyclooxygenase-2 expression in lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells.

Authors:  Sun Suk Kim; O-Jin Oh; Hye-Young Min; Eun-Jung Park; Youngleem Kim; Hyen Joo Park; Yong Nam Han; Sang Kook Lee
Journal:  Life Sci       Date:  2003-06-06       Impact factor: 5.037

10.  Signal transduction for inhibition of inducible nitric oxide synthase and cyclooxygenase-2 induction by capsaicin and related analogs in macrophages.

Authors:  Ching-Wen Chen; Sho Tone Lee; Wen Tung Wu; Wen-Mei Fu; Feng-Ming Ho; Wan Wan Lin
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

View more
  32 in total

1.  Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow-up study.

Authors:  Elizabeth D Kantor; Xuehong Zhang; Kana Wu; Lisa B Signorello; Andrew T Chan; Charles S Fuchs; Edward L Giovannucci
Journal:  Int J Cancer       Date:  2016-07-18       Impact factor: 7.396

2.  Ethanol extract of Elaeocarpus petiolatus inhibits lipopolysaccharide-induced inflammation in macrophage cells.

Authors:  Ok-Kyoung Kwon; Kyung-Seop Ahn; Ji-Won Park; Ha-Young Jang; Hyouk Joung; Hyeong-Kyu Lee; Sei-Ryang Oh
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

3.  A leaf methanolic extract of Wercklea insignis attenuates the lipopolysaccharide-induced inflammatory response by blocking the NF-κB signaling pathway in RAW 264.7 macrophages.

Authors:  Ji-Won Park; Ok-Kyoung Kwon; Ha-young Jang; Hyeok Jeong; Sei-Ryang Oh; Hyeong-Kyu Lee; Sang-Bae Han; Kyung-Seop Ahn
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

4.  Tetrahydroabietic Acid, a Reduced Abietic Acid, Inhibits the Production of Inflammatory Mediators in RAW264.7 Macrophages Activated with Lipopolysaccharide.

Authors:  Nam-Ho Kim; Yong Son; Sun-Oh Jeong; Jong Moon Hur; Han Soo Bang; Ki-Nam Lee; Eun-Cheol Kim; Hun-Taeg Chung; Hyun-Ock Pae
Journal:  J Clin Biochem Nutr       Date:  2010-02-27       Impact factor: 3.114

5.  Osteoinductive LIM mineralization protein-1 suppresses activation of NF-kappaB and selectively regulates MAPK pathways in pre-osteoclasts.

Authors:  Hui Liu; Maggie Bargouti; Susu Zughaier; Zhaomin Zheng; Yunshan Liu; Sreedhara Sangadala; Scott D Boden; Louisa Titus
Journal:  Bone       Date:  2009-11-18       Impact factor: 4.398

6.  Gallic Acid-g-Chitosan Modulates Inflammatory Responses in LPS-Stimulated RAW264.7 Cells Via NF-κB, AP-1, and MAPK Pathways.

Authors:  Chang-Bum Ahn; Won-Kyo Jung; Sun-Joo Park; Yong-Tae Kim; Won-Suk Kim; Jae-Young Je
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

7.  Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation.

Authors:  Elizabeth D Kantor; Johanna W Lampe; Sandi L Navarro; Xiaoling Song; Ginger L Milne; Emily White
Journal:  J Altern Complement Med       Date:  2014-04-16       Impact factor: 2.579

8.  Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort.

Authors:  Elizabeth D Kantor; Christina C Newton; Edward L Giovannucci; Marjorie L McCullough; Peter T Campbell; Eric J Jacobs
Journal:  Cancer Causes Control       Date:  2018-02-06       Impact factor: 2.506

9.  Association between use of specialty dietary supplements and C-reactive protein concentrations.

Authors:  Elizabeth D Kantor; Johanna W Lampe; Thomas L Vaughan; Ulrike Peters; Colin D Rehm; Emily White
Journal:  Am J Epidemiol       Date:  2012-11-08       Impact factor: 4.897

10.  Glucosamine and Chondroitin Use in Relation to C-Reactive Protein Concentration: Results by Supplement Form, Formulation, and Dose.

Authors:  Elizabeth D Kantor; Kelli O'Connell; Mengmeng Du; Chao Cao; Xuehong Zhang; Dong Hoon Lee; Yin Cao; Edward L Giovannucci
Journal:  J Altern Complement Med       Date:  2020-12-07       Impact factor: 2.579

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.